<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03459417</url>
  </required_header>
  <id_info>
    <org_study_id>SECI-Assuit</org_study_id>
    <nct_id>NCT03459417</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Intrathecally Administered Magnesium Sulfate</brief_title>
  <official_title>Safety and Efficacy of Intrathecally Administered Magnesium Sulfate Added to Morphine and Local Anesthetics for Major Abdominal Cancer Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>South Egypt Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>South Egypt Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Magnesium sulfate safety profile has been documented by histopathological analysis in
      experimental studies. magnesium sulfate added to local anesthetics decrease postoperative
      opioid requirements.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Spinal anesthesia is commonly used for the major abdominal cancer surgery because of
      decreasing the risks of general anesthesia.The quality and duration of sensory and motor
      block and decrease post operative pain is important in the major abdominal cancer surgery and
      patient's content satisfaction. Opioids in high doses and other drug such as clonidine and
      neostigmine added to local anesthetics to this purpose, but significant side effects.

      Magnesium sulfate block the N- methyle -D- aspartate (NMDA) channels in a voltage-dependent
      way to be improve the quality and duration of spinal block. However, the use of magnesium
      sulfate safety profile has been documented by histopathological analysis in experimental
      studies. Systemic delivery of magnesium sulfate decrease postoperative opioid requirements.
      In experimental studies, spinal injection of magnesium sulfate reduces the respond to painful
      stimulus in rats.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">June 1, 2019</completion_date>
  <primary_completion_date type="Actual">May 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change pain sensation using VAS scores</measure>
    <time_frame>at 0, 4, 8, 12, 18, 24, 36 and 48 hours post operative</time_frame>
    <description>pain sensation using VAS scores with movement (0-10) 0=no pain 10=worst pain ever</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in MAP</measure>
    <time_frame>at 0, 4, 8, 12, 18, 24, 36 and 48 hours post operative</time_frame>
    <description>Mean arterial pressure</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Abdominal Cancer</condition>
  <condition>Abdominal Pain</condition>
  <arm_group>
    <arm_group_label>intrathecal morphine+LA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive intrathecal 15 mg (3 mL) of LA (hyperbaric bupivacaine 0.5%) intrathecal with 0.5 mg preservative free morphine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intrathecal morphine+LA+Mg sulp. 50</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive intrathecal 15 mg (3 mL) of LA (hyperbaric bupivacaine 0.5%) intrathecal with 0.5 mg preservative free morphine + magnesium sulfate 50 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intrathecal morphine+LA+ Mg sulp.100</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive intrathecal 15 mg (3 mL) of LA (hyperbaric bupivacaine 0.5%) intrathecal with 0.5 mg preservative free morphine + magnesium sulfate 100 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>intrathecal morphine+LA</intervention_name>
    <description>Lumbar puncture will be performed in the sitting position. A 25 gauge (pencil point, Braun, Melsungen, Germany) spinal needle will be introduced into the subarachnoid space at the L3-L4 lumber level midline approach with the needle orifice cephalad. Cerebrospinal fluid will be aspirated and the ready mixture will be injected to subarachnoid space over the period of 15 s, with barbotage. patients will receive intrathecal LA 15 mg (3 mL) (hyperbaric bupivacaine 0.5%) intrathecal with 0.5 mg preservative free morphine + magnesium sulfate 100 mg.</description>
    <arm_group_label>intrathecal morphine+LA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>intrathecal morphine+LA+ Mg sulp. 50</intervention_name>
    <description>Lumbar puncture will be performed in the sitting position. A 25 gauge (pencil point, Braun, Melsungen, Germany) spinal needle will be introduced into the subarachnoid space at the L3-L4 lumber level midline approach with the needle orifice cephalad. Cerebrospinal fluid will be aspirated and the ready mixture will be injected to subarachnoid space over the period of 15 s, with barbotage.patients will receive intrathecal 15 mg (3 mL) of hyperbaric bupivacaine 0.5% intrathecal +0.5 mg preservative free morphine + magnesium sulphate 50 mg.</description>
    <arm_group_label>intrathecal morphine+LA+Mg sulp. 50</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>intrathecal morphine+LA+ Mg sulp. 100</intervention_name>
    <description>Lumbar puncture will be performed in the sitting position. A 25 gauge (pencil point, Braun, Melsungen, Germany) spinal needle will be introduced into the subarachnoid space at the L3-L4 lumber level midline approach with the needle orifice cephalad. Cerebrospinal fluid will be aspirated and the ready mixture will be injected to subarachnoid space over the period of 15 s, with barbotage.patients will receive intrathecal 15 mg (3 mL) of hyperbaric bupivacaine 0.5% intrathecal with 0.5 mg preservative free morphine + magnesium sulphate 100 mg.</description>
    <arm_group_label>intrathecal morphine+LA+ Mg sulp.100</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with ASA physical status II or III, 21-year-old or older with major abdominal
             cancer surgery

        Exclusion Criteria:

          -  significant coexisting, hepatorenal, or other end organ disease, obesity (BMI &gt; 38
             kg/m2), contraindication to regional anesthesia and sensitivity to local anesthetic
             drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>South Egypt Cancer Institute, Assiut University, Arab Republic of Egypt</name>
      <address>
        <city>Assiut</city>
        <zip>0020</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>February 21, 2018</study_first_submitted>
  <study_first_submitted_qc>March 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2018</study_first_posted>
  <last_update_submitted>December 11, 2019</last_update_submitted>
  <last_update_submitted_qc>December 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>South Egypt Cancer Institute</investigator_affiliation>
    <investigator_full_name>Alaa Ali M. Elzohry</investigator_full_name>
    <investigator_title>Lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abdominal Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Sulpiride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

